United States: Capitol Hill Healthcare Update - July 31, 2017

Editor's Note – The next Capitol Hill Healthcare Update will be published after Labor Day when Congress reconvenes following its August recess.

Republicans Contemplate Next Steps Amid ACA Flameout

Congressional Republicans and President Donald Trump face a series of key questions about how or whether to fortify the Affordable Care Act – particularly in the law's beleaguered individual exchanges – after the Senate last week failed to advance legislation overhauling the healthcare law.

When Sen. John McCain (R-Ariz.) cast the deciding vote against a slimmed-down bill eliminating parts of the ACA, it marked an extraordinary political flameout for Republicans, who have singularly campaigned against the ACA for the past seven years. Deep ideological divides among congressional Republicans and Trump's thorough inability to forge consensus between moderate and conservative lawmakers ultimately sank the GOP's bill – and likely imperils future party-line efforts to make changes to the healthcare law.

After the vote, Senate HELP Committee Chairman Lamar Alexander (R-Tenn.) said his panel would hold bipartisan hearings on next steps, and he identified the cost-sharing subsidies in the individual exchanges as a critical first step. Trump appeared to signal he would withhold future monthly payments the government is making, calling them in a tweet Saturday "bailouts" for insurers. He also tweeted this morning that insurance companies should feel the "hurt" of the ACA.

While there are bipartisan clusters of lawmakers in the House and Senate talking about fixes to the ACA, there isn't currently a majority in either chamber to advance legislation. It's not just Republicans who are in a policy and political straightjacket over healthcare. Democrats are split, too, with some calling for narrow fixes to the ACA and others pulled by the party's liberal activists pushing for a single-payer, government-run system.

Even if bipartisan fairy dust is sprinkled over Washington when lawmakers return from their summer break after Labor Day, Congress will have other legislative priorities in the fall.

Before the 2017 fiscal year expires on Sept. 30, Congress must approve a stopgap budget to keep the government open, and Trump administration officials want lawmakers to raise the government's debt ceiling before the end of September. On the healthcare front, both FDA user fees and the Children's Health Insurance Program (CHIP) will expire unless renewed by Congress in September.

Providers are also contemplating ACA next steps. Several iterations of Republicans' bills in recent months would have ended or suspended the medical device industry's 2.3 percent excise tax, which is scheduled to come back online Jan. 1 after a two-year hiatus. Technology manufacturers now will look to other legislative vehicles, like tax reform, to carry device tax repeal.

Insurers say they need clarity on cost-sharing subsidies or more companies will flee the individual markets. Already consumers in 974 counties nationwide don't have choices in health insurance because only one insurer is offering coverage, and there are no insurance options available in dozens of other counties.

White House Budget Director Mick Mulvaney on Sunday said the Senate should hold a re-vote on its ACA bill and not consider any other legislation until it passes. But the Senate isn't likely to oblige. McCain is returning to Arizona this week to continue treatment for brain cancer, and Republicans currently don't have consensus on healthcare policy – and therefore don't have the votes – to pass anything substantive related to the law they have opposed since it was enacted in 2010.

Senator Introduces Medical Device Cyber Bill

Saying medical device manufacturers don't follow best practices when it comes to cyber security, a senator introduced legislation last week that would create a series of reporting and certification requirements for medical technology companies.

Introduced by Sen. Richard Blumenthal (D-Conn.), the legislation would create a cyber report card for medical devices and require manufacturers to obtain consent from healthcare providers before remotely accessing a device. The bill would not require device manufacturers to seek a new 510(k) approval from the FDA for software updates related to cybersecurity.

The senator said that while some manufacturers offer prompt cybersecurity updates, others fail to follow cyber best practices. Blumenthal is not a member of the Senate HELP Committee, which has legislative jurisdiction over healthcare policy.

More Drug Manufacturers, Distributors Targeted in Senate Opioid Probe

A Democratic senator is adding four pharmaceutical manufacturers and three drug distributors to her investigation into the underlying causes of the opioid crisis.

Sen. Claire McCaskill (D-Mo.) wants to know whether stakeholders were aware of and reported diversion of prescribed opioids for illicit use. McCaskill sent letters to drug manufacturers Allergan, Endo, Mallinckrodt and Teva, and to opioid distributors AmerisourceBergen, Cardinal Health and McKesson.

McCaskill is the top Democrat on the Homeland Security and Governmental Affairs Committee. She is leading the opioid examination for the most part independently of Committee Chairman Ron Johnson (R-Wis.). But cracking down on opioid abuse is also priority for Johnson, whose nephew died of a heroin overdose after earlier abusing opioids following a sports injury.

The attorney general from McCaskill's home state of Missouri, Josh Hawley, filed suit against three pharmaceutical companies in June for allegedly violating the state's Medicaid fraud and consumer-protection statutes by "misrepresenting the truth" about opioids. He said that in 2015, 500 Missouri residents died of opioid overdoses or complications and 300 more died from heroin abuse.

House OKs Medicare Payment Change

The House last week approved legislation that would make a series of changes to Medicare payment policies, including extending coverage for at-home end-stage renal disease treatment.

The bill won House approval on a voice vote and now moves to the Senate for consideration. It was introduced by House Ways and Means Committee Chairman Kevin Brady (R-Texas).

The medical innovation law 21st Century Cures, which Congress approved last year, changes the way Medicare reimburses for the acquisition of home infusion drugs. Brady's bill would create a payment structure for home infusion.

It also would expand a Medicare telehealth program for people with end-stage renal disease, codify recent changes to physician self-referral rules and make it easier for Medicare beneficiaries to get customized orthotics and prosthetics.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions